GTG — Genetic Technologies Income Statement
0.000.00%
Last trade - 00:00
- AU$13.85m
- AU$10.50m
- AU$8.69m
2019 June 30th | C2020 June 30th | C2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.025 | 0.01 | 0.121 | 6.79 | 8.69 |
Cost of Revenue | |||||
Gross Profit | -0.251 | -0.092 | -0.05 | 3.78 | 4.35 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 6.43 | 6.29 | 7.52 | 14.4 | 21 |
Operating Profit | -6.41 | -6.28 | -7.4 | -7.57 | -12.3 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.43 | -6.29 | -7.08 | -7.16 | -11.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.43 | -6.29 | -7.08 | -7.13 | -11.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.43 | -6.29 | -7.08 | -7.13 | -11.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.43 | -6.29 | -7.08 | -7.13 | -11.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.21 | -0.158 | -0.086 | -0.077 | -0.102 |